Skip to main content
. 2023 Sep 14;54(1):31–37. doi: 10.1093/jjco/hyad125

Figure 1.

Figure 1

Comparison of progression-free survival (PFS) in patients with germline BRCA (gBRCA) pathogenic variants, homologous recombination deficiency (HRD), gBRCA wild-type, variant of unknown significance (VUS), homologous recombination proficiency (HRP) and not analyzed patients with maintenance treatment for platinum-sensitive advanced ovarian cancer.